Conclusions
TAPSE may be one of the independent significant predictors of CV events in patients with MR undergoing MitraClip therapy. TAPSE may be measured prior to MitraClip therapy as a simple and easy parameter of RV function to predict worse outcomes in a MitraClip cohort.